secwatch.observer — SEC 8-K summary
======================================

Issuer:     Abpro Holdings, Inc. (ABPO)
CIK:        0001893219
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001193125-24-257374
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abpro Holdings completes SPAC merger; to trade on Nasdaq under 'ABP' starting Nov. 14
--------------------------------------------------------------------------------

- Business combination between Abpro Corporation and Atlantic Coastal Acquisition Corp. II closed; approved by Atlantic Coastal stockholders on Nov. 7.
- Common stock to trade on Nasdaq Global Market under 'ABP'; warrants on Nasdaq Capital Market under 'ABPWW' beginning Nov. 14, 2024.
- Celltrion invested $5 million in a PIPE transaction and gained a board seat (Soo Young Lee).
- Abpro focuses on next-gen antibody therapies for HER2+ cancers, Wet AMD/DME, and COVID-19 using DiversImmune platform.
- Exclusive collaboration with Celltrion on ABP 102 (t-cell engager) for HER2+ breast, gastric, and pancreatic cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1893219/000119312524257374/0001193125-24-257374-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1893219/000119312524257374/d873918d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-257374

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer